Johnson & Johnson: Psoriasis trials

The registry lists 64 Psoriasis studies with Johnson & Johnson as lead sponsor. 3 are open to participants now and 28 have results posted.

Early Phase 1 1Phase 1 5Phase 2 10Phase 3 27Phase 4 4No phase 18(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Guselkumab Given After Ustekinumab in Participants With Moderate to Severe Psoriasis in Routine Clinical PracticeRecruitingNCT07746583
• A Remotely Conducted Study to Assess Concentration of TREMFYA in Breast Milk of Lactating Women Who Are Receiving TREMFYA TherapeuticallyRecruitingNCT07654751Phase 4
• A Study of Persistence to Guselkumab Treatment in Participants With Moderate-to-Severe Plaque Psoriasis in RomaniaRecruitingNCT07582783
• A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisActive, not recruitingNCT06295692Phase 3Results posted
• Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque PsoriasisTerminatedNCT05125679Phase 4Results posted
• A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type PsoriasisCompletedNCT03818035Phase 3Results posted
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric ParticipantsActive, not recruitingNCT03451851Phase 3Results posted
• A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type PsoriasisCompletedNCT03090100Phase 3Results posted
• A Study to Compare the Efficacy of Guselkumab to Fumaric Acid Esters for the Treatment of Participants With Moderate to Severe Plaque PsoriasisCompletedNCT02951533Phase 3Results posted
• Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type PsoriasisCompletedNCT02905331Phase 3Results posted
• An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of AgeCompletedNCT02698475Phase 3Results posted
• An Efficacy and Safety of Guselkumab in Participants With Palmoplantar PustulosisCompletedNCT02641730Phase 3Results posted
• Phase 3 Study of M923 and Humira® in Subjects With Chronic Plaque-type PsoriasisCompletedNCT02581345Phase 3Results posted
• An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type PsoriasisCompletedNCT02325219Phase 3Results posted
• A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type Psoriasis With Randomized Withdrawal and RetreatmentCompletedNCT02207244Phase 3Results posted
• A Study of Guselkumab in the Treatment of Participants With Moderate to Severe Plaque-Type PsoriasisCompletedNCT02207231Phase 3Results posted
• A Study of Guselkumab in Participants With Moderate to Severe Plaque-type Psoriasis and an Inadequate Response to UstekinumabCompletedNCT02203032Phase 3Results posted
• A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque PsoriasisCompletedNCT01550744Phase 3Results posted
• A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type PsoriasisCompletedNCT01483599Phase 2Results posted
• A Study to Evaluate Safety and Efficacy of Infliximab in Chinese Participants With Moderate to Severe Plaque-type PsoriasisCompletedNCT01177800Phase 3Results posted
• A Study of the Safety and Efficacy of Ustekinumab in Adolescent Patients With Psoriasis (CADMUS)CompletedNCT01090427Phase 3Results posted
• A Safety and Efficacy Study of Ustekinumab in Patients With Plaque Psoriasis Who Have Had an Inadequate Response to MethotrexateCompletedNCT01059773Phase 4Results posted
• A Study of the Safety and Effectiveness of Ustekinumab (Stelara) in Chinese Patients With PsoriasisCompletedNCT01008995Phase 3Results posted
• An Observational Study of Infliximab Injection in Ankylosing Spondylitis, Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis ParticipantsCompletedNCT00760669Results posted
• A Phase 3 Trial to Look at the Safety and Effectiveness of Ustekinumab in Korean and Taiwanese Subjects With Moderate to Severe Plaque-type PsoriasisCompletedNCT00747344Phase 3Results posted
• An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque PsoriasisCompletedNCT00723528Phase 3Results posted
• PSUNRISE - Prospective Study Using Remicade in Psoriasis Patients With an Inadequate Response to EtanerceptCompletedNCT00527072Phase 3Results posted
• An Efficacy and Safety Study of CNTO 1275 Compared to Etanercept in Patients With Plaque PsoriasisCompletedNCT00454584Phase 3Results posted
• A Safety and Effectiveness Study of CNTO 1275 in Patients With Moderate to Severe Plaque-type PsoriasisCompletedNCT00320216Phase 2Results posted
• A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe PsoriasisCompletedNCT00307437Phase 3Results posted
• A Study of Safety and Effectiveness of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Plaque-type PsoriasisCompletedNCT00267969Phase 3Results posted
• A Study of Guselkumab After Switching From Ustekinumab in Participants With Moderate to Severe PsoriasisTerminatedNCT07449234
• A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or PsoriasisCompletedNCT05252533Phase 1
• A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque PsoriasisCompletedNCT04914429Phase 4
• A Registry Study of Palmoplantar Pustulosis (PPP) Treatment Patterns, Disease Burden and Treatment Outcomes in JapanCompletedNCT04459507
• A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) PsoriasisCompletedNCT04439526
• A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular PsoriasisCompletedNCT03998683Phase 3
• Analysis of Non-Invasively Collected Microneedle Device Samples From Mild Plaque Psoriasis for Use in Transcriptomics ProfilingCompletedNCT03795402
• A Safety Study of Ustekinumab in the Treatment of Pediatric Participants Aged 6 Years and Older With Moderate to Severe Plaque PsoriasisActive, not recruitingNCT03218488
• Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With PsoriasisCompletedNCT02397382Phase 1
• An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic PsoriasisCompletedNCT02343744Phase 3
• A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type PsoriasisCompletedNCT02295865Phase 2
• A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type PsoriasisCompletedNCT02274363
• Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque PsoriasisTerminatedNCT02243787Phase 1/2
• An Exploratory Genetic Study in Participants With PsoriasisCompletedNCT02155192
• Clinical Assessment and Psychosocial Impact of PsoriasisCompletedNCT01964443
• A Study of the Efficacy, Safety and Tolerability of CNTO 1959, a Human Anti-IL 23 Monoclonal Antibody in Participants With Palmoplantar PustulosisCompletedNCT01845987Phase 2
• A Study to Evaluate Ustekinumab in Patients With Plaque Psoriasis in Asia-Pacific CountriesCompletedNCT01677598
• An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque PsoriasisCompletedNCT01555606
• A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque PsoriasisCompletedNCT01484587Phase 1
• Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe PsoriasisCompletedNCT01384630Phase 2
• A Study to Assess the Clinical Profile of Patients in Spain With Moderate to Severe Psoriasis.CompletedNCT01262534
• ACT-128800 in Patients With Moderate to Severe Chronic Plaque PsoriasisCompletedNCT01208090Phase 2
• Ustekinumab Safety and Surveillance Program Using the Ingenix NHI DatabaseCompletedNCT01081730
• A Study of the Safety and How the Body Affects a Drug (CNTO 1959) in Healthy Volunteers and in Patients With PsoriasisCompletedNCT00925574Phase 1
• ACT-128800 in PsoriasisCompletedNCT00852670Phase 2
• Analysis of Birth Outcomes of Swedish, Danish and Finnish Women Exposed to Remicade With Inflammatory Bowel Disease, Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, and PsoriasisCompletedNCT00658827
• A Study to Test the Design, Functionality, and Ergonomic Features of the AutoinjectorCompletedNCT00643526Early Phase 1
• Psoriasis Longitudinal Assessment and RegistryActive, not recruitingNCT00508547
• Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque PsoriasisCompletedNCT00396422Phase 2
• A Long-term Safety Study of Infliximab (Remicade)CompletedNCT00261976
• A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type PsoriasisCompletedNCT00230529Phase 2
• A Study of the Safety and Effectiveness of Infliximab in Patients With Plaque-type PsoriasisCompletedNCT00106847Phase 3
• A Study of the Safety and Efficacy of Infliximab in Patients With PsoriasisCompletedNCT00106834Phase 3